AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Reid Hoffman’s Exit From Microsoft Board Highlights the Pull of AI Drug Discovery
Reid Hoffman will leave Microsoft’s board to focus on Manas AI, a startup working on AI drug discovery. The move reflects how seriously some prominent tech investors now view the opportunity in computational biology and therapeutics.
Insilico Medicine’s CEO Earns Recognition as AI Drug Discovery Gains Scientific Legitimacy
Insilico Medicine founder and CEO Alex Zhavoronkov has been recognized in the inaugural SCW75 for pioneering AI-driven drug discovery and longevity research. The honor reflects growing institutional acceptance of AI-native biotech leadership.
Pfizer Doubles Down on AI Drug Discovery With Chai Discovery License
Pfizer has signed a new licensing agreement with Chai Discovery to accelerate drug discovery with AI, adding to the pharma giant’s growing portfolio of AI bets. The move underscores how big drugmakers are increasingly seeking platform access rather than single-purpose tools.
Pfizer and Eli Lilly Back $1.3 Billion AI Drug Discovery Startup as Industry Competition Intensifies
Pfizer and Eli Lilly are among the companies betting on a $1.3 billion AI drug discovery startup, underscoring the growing race to secure access to next-generation discovery platforms. The investment reflects how pharma giants are increasingly treating AI as strategic infrastructure.
Recursion’s AI Pipeline Is Facing the Hard Part: Investor Patience
A new look at Recursion says progress in its AI drug pipeline is testing investor patience and valuation. The company’s experience highlights a broader challenge for AI-native biotechs: translating platform momentum into predictable clinical value.
Alnylam, Inceptive Form AI Drug Discovery Collaboration as the Field Consolidates
Alnylam and Inceptive have announced an AI drug discovery collaboration, adding another major partnership to a rapidly crowded sector. The deal shows how quickly pharma is moving from curiosity to multi-partner experimentation.
AI Drug Discovery Is Spreading, but the Real Debate Is Whether It’s Infrastructure or Theater
A new analysis frames AI discovery’s expansion in Asia as a test of whether the field is building durable scientific infrastructure or simply expensive demos. The debate is becoming central as partnerships and capital accelerate across the sector.
Beijing’s Push for AI Drug Discovery Could Reshape China’s Biotech Strategy
China’s new mandate for AI drug discovery and surgical robots shows the state is treating intelligent medicine as strategic infrastructure. The policy could accelerate commercialization, but it will also test whether top-down support can produce durable innovation rather than simply scale.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.